XPR – Lifestyle Demo
Author:
Knight Therapeutics
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
March 17, 2026
Notice of Knight Therapeutics’ Fourth Quarter and Year End 2025 Results Conference Call
March 12, 2026
←
Previous Page
1
2